IRVINE, Calif.--(BUSINESS WIRE)--

Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against Seres Therapeutics (“Seres” or the “Company”) (Nasdaq: MCRB). Investors who purchased or otherwise acquired shares between June 25, 2015 and July 29, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the November 28, 2016 lead plaintiff motion deadline.

If you purchased shares of Seres during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Seres made materially false and misleading statements and/or failed to disclose material facts about its lead drug product candidate SER-109, praising its potential and efficacy. On July 29, 2016, the Company announced that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this information was released to the public, shares of Seres dropped in value, which caused investors harm.

If you wish to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161005006525/en/